RSLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RSLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Reshape Lifesciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $1.49 Mil. Reshape Lifesciences's Total Assets for the quarter that ended in Sep. 2024 was $5.62 Mil. Therefore, Reshape Lifesciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.27.
The historical rank and industry rank for Reshape Lifesciences's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Reshape Lifesciences was 0.93. The lowest was -0.35. And the median was 0.52.
The historical data trend for Reshape Lifesciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reshape Lifesciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.61 | 0.39 | 0.84 | 0.33 | 0.63 |
Reshape Lifesciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.39 | 0.63 | 0.55 | 0.48 | 0.27 |
For the Medical Devices subindustry, Reshape Lifesciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Reshape Lifesciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Reshape Lifesciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 6.663 | / | 10.663 | |
= | 0.62 |
Reshape Lifesciences's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as
Equity to Asset (Q: Sep. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1.487 | / | 5.615 | |
= | 0.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reshape Lifesciences (NAS:RSLS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Reshape Lifesciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Stankovich | officer: Chief Financial Officer | 1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
Paul F. Hickey | director, officer: President and CEO | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Barton P. Bandy | director | 1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
Mcdougal Lori Courtney | director | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Arda Phd Minocherhomjee | director | C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606 |
Dan W Gladney | director | 2800 PATTON ROAD, ST. PAUL MN 55113 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Gary Blackford | director | 7700 FRANCE AVENUE SOUTH, EDINA MN 55435 |
Robert J Macdonald | officer: Chief Retail Officer | C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Daina Schmidt | officer: Vice President of Marketing | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008 |
Gilbert H Kliman | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Arnold L Oronsky | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Khaled Nasr | 10 percent owner | 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022 |
Interwest Partners X Lp | 10 percent owner | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
From GuruFocus
By GuruFocus Research • 08-16-2024
By Marketwired • 09-19-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 04-02-2024
By PRNewswire • 07-22-2024
By GuruFocus News • 11-15-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 11-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.